Must See: A Powerful Investing Opportunity is Emerging this Election Year
Here is the latest financial fact sheet of SUVEN LIFE SCIENCES. For more details, see the SUVEN LIFE SCIENCES quarterly results and SUVEN LIFE SCIENCES share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 1.8 |
No. of shares | m | 218.07 |
1 Week | % | -0.8 |
1 Month | % | -6.0 |
1 Year | % | 75.3 |
52 week H/L | Rs | 128.8/55.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
SUVEN LIFE SCIENCES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 338 | 335 | 109 | 124 | 94 | |
Low | Rs | 169 | 20 | 19 | 70 | 45 | |
Sales per share (Unadj.) | Rs | 22.4 | 1.1 | 1.1 | 0.8 | 0.6 | |
Earnings per share (Unadj.) | Rs | -1.9 | -7.4 | -5.7 | -8.4 | -5.4 | |
Diluted earnings per share | Rs | -1.1 | -4.3 | -3.3 | -5.6 | -5.4 | |
Cash flow per share (Unadj.) | Rs | -0.8 | -7.1 | -5.3 | -8.1 | -5.1 | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.88 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0.6 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 18.8 | 11.3 | 5.6 | 6.6 | 17.2 | |
Adj. book value per share | Rs | 11.0 | 6.6 | 3.3 | 4.4 | 17.2 | |
Shares outstanding (eoy) | m | 127.28 | 127.28 | 127.28 | 145.38 | 218.07 | |
Price / Sales ratio | x | 11.3 | 156.8 | 60.6 | 119.6 | 111.8 | |
Avg P/E ratio | x | -135.0 | -24.0 | -11.3 | -11.6 | -12.8 | |
P/CF ratio (eoy) | x | -332.4 | -25.1 | -12.0 | -12.0 | -13.5 | |
Price / Book Value ratio | x | 13.5 | 15.8 | 11.5 | 14.7 | 4.0 | |
Dividend payout | % | -79.9 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 32,269 | 22,605 | 8,168 | 14,164 | 15,131 | |
Total wages/salary | Rs m | 365 | 174 | 185 | 210 | 186 |
SUVEN LIFE SCIENCES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 2,857 | 144 | 135 | 118 | 135 | |
Other income | Rs m | 272 | 140 | 78 | 16 | 84 | |
Total revenues | Rs m | 3,129 | 285 | 212 | 134 | 220 | |
Gross profit | Rs m | -110 | -1,157 | -799 | -1,185 | -1,196 | |
Depreciation | Rs m | 142 | 42 | 43 | 44 | 65 | |
Interest | Rs m | 19 | 6 | 9 | 7 | 5 | |
Profit before tax | Rs m | 2 | -1,064 | -775 | -1,220 | -1,183 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 241 | -122 | -53 | 0 | 0 | |
Profit after tax | Rs m | -239 | -942 | -722 | -1,220 | -1,183 | |
Gross profit margin | % | -3.8 | -802.8 | -593.1 | -1,000.8 | -883.6 | |
Effective tax rate | % | 15,423.1 | 11.4 | 6.9 | 0 | 0 | |
Net profit margin | % | -8.4 | -653.6 | -535.3 | -1,030.0 | -873.5 |
SUVEN LIFE SCIENCES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 3,982 | 1,595 | 1,966 | 1,605 | 3,455 | |
Current liabilities | Rs m | 1,570 | 1,200 | 1,098 | 1,022 | 1,050 | |
Net working cap to sales | % | 84.5 | 273.8 | 643.8 | 492.1 | 1,776.0 | |
Current ratio | x | 2.5 | 1.3 | 1.8 | 1.6 | 3.3 | |
Inventory Days | Days | 285 | 2,312 | 2 | 1,402 | 3,948 | |
Debtors Days | Days | 34 | 575 | 477 | 400 | 218 | |
Net fixed assets | Rs m | 224 | 1,159 | 257 | 414 | 1,373 | |
Share capital | Rs m | 127 | 127 | 127 | 145 | 218 | |
"Free" reserves | Rs m | 2,264 | 1,306 | 584 | 816 | 3,535 | |
Net worth | Rs m | 2,391 | 1,433 | 711 | 961 | 3,753 | |
Long term debt | Rs m | 18 | 11 | 4 | 0 | 0 | |
Total assets | Rs m | 4,206 | 2,755 | 2,223 | 2,019 | 4,828 | |
Interest coverage | x | 1.1 | -192.1 | -81.3 | -181.1 | -218.8 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.7 | 0.1 | 0.1 | 0.1 | 0 | |
Return on assets | % | -5.2 | -34.0 | -32.0 | -60.1 | -24.4 | |
Return on equity | % | -10.0 | -65.7 | -101.5 | -126.9 | -31.5 | |
Return on capital | % | 0.9 | -73.3 | -107.1 | -126.2 | -31.4 | |
Exports to sales | % | 196.8 | 94.2 | 69.1 | 44.7 | 40.4 | |
Imports to sales | % | 63.0 | 877.5 | 547.1 | 933.6 | 839.8 | |
Exports (fob) | Rs m | 5,622 | 136 | 93 | 53 | 55 | |
Imports (cif) | Rs m | 1,799 | 1,265 | 737 | 1,106 | 1,137 | |
Fx inflow | Rs m | 5,622 | 136 | 93 | 53 | 55 | |
Fx outflow | Rs m | 1,799 | 1,265 | 737 | 1,106 | 1,137 | |
Net fx | Rs m | 3,822 | -1,129 | -644 | -1,053 | -1,082 |
SUVEN LIFE SCIENCES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -526 | -1,346 | -960 | -1,275 | -1,031 | |
From Investments | Rs m | 371 | 1,462 | 558 | -222 | -2,606 | |
From Financial Activity | Rs m | 45 | 28 | 349 | 1,457 | 3,955 | |
Net Cashflow | Rs m | -177 | 144 | -53 | -41 | 317 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Venkateswarlu Jasti | COMP SEC: Shrenik Soni | YEAR OF INC: 1989 | BSE CODE: 530239 | FV (Rs): 1 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB CIPLA ZYDUS LIFESCIENCES SUN PHARMA
Compare SUVEN LIFE SCIENCES With: DIVIS LABORATORIES DR. REDDYS LAB CIPLA ZYDUS LIFESCIENCES SUN PHARMA
Asian stocks fell on Friday, while the dollar advanced as strong US economic data bolstered the prospect of interest rates staying higher for longer.